• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins

in

Drugs (Pharmaceuticals), Eli Lilly and Company, Food and Drug Administration, GLP-1 RAs (Drug), Hims & Hers Health Inc, Jorgensen, Lars Fruergaard, Makary, Marty, Novo Nordisk A/S, Obesity, Prices (Fares, Fees and Rates), Shortages, Telemedicine
←Shein and Temu Will be Hit by Trump’s China Tariffs. Americans Are Worried.
The Concert Cold War in a Quiet Enclave→

More posts

  • Rihanna’s Beverly Hills home hit by gunfire; suspect arrested, LAPD says

  • Alexander brothers found guilty on all counts in sex trafficking trial

  • Fashionable Wall Street Bros Set Off a Social Media Storm

  • Casey Wasserman’s name dropped from agency following Ghislaine Maxwell scandal

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube